NEW YORK, July 31, 2006 (PRIMEZONE) -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on Lincoln, Rhode Island-based MultiCell Technologies, Inc. (OTCBB:MCET). The full 48-page report can be found at www.crystalra.com and www.multicelltech.com.
MultiCell Technologies, Inc. ("MultiCell" or "the Company") is an integrated biopharmaceutical company that uses proprietary immune system modulation technologies to discover and commercialize new therapeutics. The Company's expertise in Toll-like receptor (TLR) and T-Cell tolerance technologies has lead to the discovery of new therapeutics for the treatment of degenerative neurological disease such as multiple sclerosis (MS); metabolic and endocrinological disorders such as Type 1 diabetes, hepatitis, and sepsis; degenerative ocular disorders such as macular degeneration; and infectious disease such as influenza A. MultiCell's therapeutic pipeline includes MCT-125, directed at fatigue in MS; MCT-175, targeting relapse-remitting MS (RR-MS); MCT-275, targeting treatment of Type 1 diabetes; MCT-355, directed at macular degeneration; and MCT-465, addressing influenza A. MultiCell also specializes in developing primary cell immortalization technologies to produce cell-based assay systems for use in drug discovery. The Company has partnered this technology with large capitalization pharmaceutical companies, including Pfizer, Inc. (PFE-NYSE), Bristol-Myers Squibb Co. (BMY-NYSE), and Eisai Co., Ltd. to evaluate drug candidates for cytochrome P450 induction and toxicity.
About Crystal Research Associates, LLC
Crystal Research Associates, LLC is an independent research firm that provides institutional-quality fee-based research to small and mid-cap companies. The Company's unique and novel product, the Executive Informational Overview(R) (EIO(R)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(R) presents a crystal-clear, detailed report on a company (whether public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(R) details a company's product/technology/service offerings, market size(s), key intellectual property (IP), leadership, growth strategy, competition, risks, audited financial statements, key events and other such fundamental information. Crystal Research Associates has offices in New York City, Delray Beach, Montreal, and Toronto. Crystal Research Associates has been compensated by the Company in cash of US$35,000 and 200,000 warrants for its services in creating this report, for updates, and for printing costs. Principals in Crystal Research Associates own shares of MultiCell Technologies, Inc. Common Stock, which were purchased in the open market.
Forward-Looking Safe Harbor Statement
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of the Company's technology, opportunities for the Company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of the Company's intellectual property, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including Forms 10-KSB, 10-QSB, 8-K, and other forms filed with the Securities and Exchange Commission ("SEC") from time to time.
These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates, LLC assumes no obligation to update any of the forward looking statements in this release.